Further evidence for the long-term safety of guselkumab
Br J Dermatol
.
2023 Jul 7;189(1):10-11.
doi: 10.1093/bjd/ljad161.
Author
Antonia Lloyd-Lavery
1
Affiliation
1
Department of Dermatology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
PMID:
37177897
DOI:
10.1093/bjd/ljad161
No abstract available
Publication types
Editorial
Comment
MeSH terms
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized* / adverse effects
Humans
Psoriasis* / drug therapy
Substances
guselkumab
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal